Potential for prokinetics use in gastroenterological practice
- Authors: Agafonova NA1, Yakovenko EP1, Pryanishnikova AS1, Kazarina AV1, Yakovenko AV1, Ivanov AN1, Nazarbekova RS1, Grigor'eva Y.V1, Agafonova NA1, Jakovenko EP1, Pryanishnikova AS1, kazarina AV1, Jakovenko AV1, Ivanov AN1, Nazarbekova RS1, Grigoryeva Y.V1
-
Affiliations:
- Issue: No 10 (2009)
- Pages: 37-42
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/277207
- ID: 277207
Cite item
Full Text
Abstract
About the authors
N A Agafonova
E P Yakovenko
A S Pryanishnikova
A V Kazarina
A V Yakovenko
A N Ivanov
R S Nazarbekova
Yu V Grigor'eva
N A Agafonova
E P Jakovenko
A S Pryanishnikova
A V kazarina
A V Jakovenko
A N Ivanov
R S Nazarbekova
Yu V Grigoryeva
References
- Григорьев П.Я., Яковенко Э.П. Краткое формулярное руководство по гастроэнтерологии и гепатологии. М., 2003. 112 с.
- Григорьев П.Я., Яковенко Э.П., Агафонова Н.А. и др. Церукал в гастроэнтерологической практике // Фарматека. 2003. № 10(73). С. 24-27.
- Машковский М.Д. Лекарственные средства. 13 изд. I том. С. 186.
- Яковенко Э.П., Григорьев П.Я., Агафонова Н.А. и др. Рвота и тошнота: патогенез, этиология, диагностика, лечение // Фарматека. 2005. № 1. С. 58-61.
- Arora AS, Castell DO. Medical Therapy for gastroesophageal reflux disease. Mayo Clin Proc 2001;76:102-06.
- Attar BM, Demetria MV, Chen Y. Is gastric myoelectric activity by associated with symptoms in patient with functional dyspepsia? DDW New Orleans 1998;abstr. PA 380.
- Baeryens R, van de Velde E, de Schepper A, et al. Effects of intravenosus and oral domperidon on the motor function of the stomach and small intestine. Postgraduate Med J 1979;55(Supll. 1):19-23.
- Broggden R, Carmine A, Heel R, et al. Domperidon: a review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drug 1988;1:1-34.
- De Vault KR, et al. ACG Treatment Guideline: Updated Guidelines for diagnosis and treatment of gastroesophageal reflux disease. 1999;94(6):1434-42.
- Drossman DA. The Functional Gastrointestinal Disoders and the Rome III Process. Gastroenterology 2006;130(5):1377-90.
- Heykants J, Hendriks R, Meuldermans W, et al. On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokinet 1981;6:61-70.
- Huang Y-C, Colaizzi JL, Bierman RH, et al. Pharmacokinetics and dose proportionality of domperidone in healthy volunteers. J Clin Pharmacol 1986;26:628-32.
- Koch KL. Motiliti disoders of the stomach. Ynnovation toward better D.I. care, Janssen-Cilag congress. Abstracts - Madrid, 1999:20-21.
- Patterson D, Silvers D, Kipnes M, et al. Does gastric emptying status in patients with diabetes influence the effectiveness of domperidone (abstract). Gastroenterology 1997;112:A804.
- Physicians' Desk Reference. http://www.pdr.net
- Sawant P, Das HS, Desai N, et al. J Assoc Physicians India 2004;52:626-28. Related Articles, Links. Comparative evaluation of the efficacy and tolerability of itopride hydrochloride and domperidone in patients with non-ulcer dyspepsia.
- Shuster MM. Atlas of gastroentestinal motiliti in Health and Disease. 2002 Hamilton London 472.
- Smout MD, Arrermans PhD. Normal and disturbed Motility of the gastrointestinal tract. 1992 РА 313.
- Weihrauch T, Forster C, Krieglsten J. Evaluation of the effect of domperidon on human oesophageal and gastroduodenal motility by intraluminal manometry. Postgraduate Med J 1979;55(Suppl. 1):7-11.
- Valenzuela JE, Dooley CP. Dopamine antagonists in the upper gastrointestinal tract. Scand J Gastroenterol 1984;19(Suppl. 96):127-36.